<span item_type="fundamental" item_id="04c5872aa92122a03e71cfcd2ad76dcf" counter_id="ST/US/GXAI" env="prod"></span><span item_type="announcement" item_id="582437347070971521" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 498.27 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.14.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -1.471 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenue</strong>: For the three months ended September 30, 2025, total revenue was $498,271, primarily from RNK Health’s non-clinical services ($441,228), subscription services ($57,042), and in-app game items ($1). For the nine months ended September 30, 2025, total revenue was $692,974, with RNK Health contributing $634,178, subscription services $57,648, and in-app game items $24.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1895618/000121390025110000/ea0264296-10q_gaxos.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: For the three months ended September 30, 2025, net loss was - $1,140,873, compared to - $864,410 for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $3,197,507, compared to - $2,585,793 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1895618/000121390025110000/ea0264296-10q_gaxos.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses for the three months ended September 30, 2025, were $1,813,026, an increase from $908,573 in 2024. For the nine months ended September 30, 2025, operating expenses were $4,382,118, up from $2,806,934 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1895618/000121390025110000/ea0264296-10q_gaxos.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the nine months ended September 30, 2025, net cash used in operations was - $3,120,632, compared to - $2,512,166 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1895618/000121390025110000/ea0264296-10q_gaxos.htm"></span></li><li><strong>Net Cash Used in Investing Activities</strong>: For the nine months ended September 30, 2025, net cash used in investing activities was - $10,363,284, compared to net cash provided by investing activities of $842,604 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1895618/000121390025110000/ea0264296-10q_gaxos.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Short-term Investments</strong>: As of September 30, 2025, short-term investments were valued at $12,058,377, compared to $2,167,419 as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1895618/000121390025110000/ea0264296-10q_gaxos.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue developing AI solutions in health and entertainment, with a focus on expanding Gaxos Labs and Gaxos Health. The company expects to continue generating operating losses in the near future due to corporate overhead and R&amp;D costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1895618/000121390025110000/ea0264296-10q_gaxos.htm"></span></li><li><strong>Non-Core Business</strong>: RNK Health, a subsidiary, is providing non-clinical administrative services and plans to expand its offerings in partnership with Nekwellness.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1895618/000121390025110000/ea0264296-10q_gaxos.htm"></span></li></ul>

Gaxos.ai | 10-Q: FY2025 Q3 Revenue: USD 498.27 K